Pharmafile Logo
Pharmafocus logo
Advanced Search
FDA sign

FDA approves Lilly/Boehringer Lantus biosimilar

December 17, 2015
Medical Communications, Sales and Marketing Basaglar, Boehringer Ingelheim, Eli Lilly, Lantus, Sanofi, abasaglar, biosimilar, diabetes, insulin, lilly

The FDA has approved Eli Lilly and Boehringer Ingelheim’s long-acting insulin Basaglar (insulin glargine injection – a biosimilar to rival Sanofi’s …

News
ABPI code

Pharma company accused of ‘bribing’ prescribers slammed by PMCPA

December 17, 2015
Medical Communications ABPI Code, Daily Telegraph, PMCPA, Prescription Medicines Code of Practice Authority, Stirling Anglian

Stirling Anglian, the company at the centre of media criticism for arranging meetings at lavish hotels in an attempt to …

News
Shkreli KaloBios

Turing chief exec Martin Shkreli arrested

December 17, 2015
Medical Communications, Sales and Marketing Daraprim, FBI, Martin Shkreli, Shkreli, turing

Turing chief executive Martin Shkreli has been arrested on a charge of securities fraud relating to a company he founded, …

News
National Institutes of Health building

Clinical trials increasingly funded by pharma industry

December 17, 2015
Research and Development JAMA, Journal of the American Medical Association, NIH, National Institutes of Health, clinical trials, clinicaltrials.gov, pharma, research

The number of clinical trials funded by pharma has risen significantly since 2006, while the number funded by the US …

News

AstraZeneca to buy majority share in Acerta Pharma

December 17, 2015
Sales and Marketing Acerta Pharma, AstraZeneca, acalabrutinib, acquisitions, mergers

Following several days of speculation, AstraZeneca has announced that it has agreed a deal to buy Acerta Pharma, a developer …

News
kelner_rob_070427

Valeant hires attorney and crisis management firm to handle bad US PR

December 17, 2015
Medical Communications, Sales and Marketing Robert Kelner, Valeant, Vianovo. Covington & Burling

Valeant has retained attorney Robert Kelner, a partner at the law firm Covington & Burling, to help the beleaguered pharma …

Appointment
csm_297_1444449899_5ce719038f

US ‘star’ Bradner to head Novartis Institute of Biomedical Research

December 17, 2015
Research and Development James Bradner, Jay Bradner, Mark Fishman, Novartis, Novartis Institute for Biomedical Research

Novartis has hired James ‘Jay’ Bradner, from Harvard’s Dana-Farber Cancer Institute, to head its Institutes for Biomedical Research from 1 …

Appointment
Sovaldi bottle

Gilead’s Sovaldi wins Drug Discovery of the Year Award

December 16, 2015
Research and Development British Pharmacological Society, Gilead, Gilead Sciences, hepatitis C, sofosbuvir, sovaldi

Gilead Science’s hepatitis C treatment Sovaldi has been awarded the British Pharmacological Society’s prestigious Drug Discovery of the Year 2016. …

News
john_sentamu

Archbishop of York to become patron of national charity tackling superbugs

December 16, 2015
antibiotic resistance

Antibiotic Research UK (ANTRUK), a charity founded in 2014 to save modern medicine from the onslaught of superbugs, has announced …

Appointment
jessica_fine

MSD UK appoints Jessica Fine as executive director of external affairs

December 16, 2015
Medical Communications Jessica Fine, MSD

MSD has appointed former Lexington Health boss Jessica Fine to lead its external affairs team in the UK from April …

Appointment

New final NICE guidance on AbbVie, BMS, Pfizer and Roche drugs

December 16, 2015
Sales and Marketing BioMarin Pharma, Enbrel, Humira, Ikervis, MPS IVa, NICE, NICE guidance, Orencia, RoActemra, Santen, apremilast, ciclosporin, dry eye syndrome, juvenile idiopathic arthritis, otezla, psoriatic arthritis, vimizin

NICE has published final guidance on several drugs, approving therapies for juvenile idiopathic arthritis, dry eye disease and Morquio A …

News
tony_gardiner

Avacta appoints Tony Gardiner as chief financial officer

December 16, 2015
Medical Communications Avacta Group

Avacta Group, the developer of Affimer biotherapeutics and research reagents, has appointed Tony Gardiner as group chief financial officer. Gardiner …

Appointment
Return on investment

Analysts say pharma R&D returns challenged by drag of high costs

December 16, 2015
Research and Development, Sales and Marketing R&D, drug development, research and development, return of investment, sales, sales forecasts

The projected rate of return on pharma industry research and development has more than halved since 2010, from 10.1% to …

News
juan_luciano

Juan Luciano appointed to Eli Lilly board

December 16, 2015
Medical Communications Eli Lilly

The board of directors of Eli Lilly has elected Juan Luciano as a new member, effective February 1 2016. Luciano …

Appointment

AstraZeneca to acquire Takeda’s respiratory franchise

December 16, 2015
Manufacturing and Production, Research and Development AstraZeneca, China, Takeda, investment, respiratory

AstraZeneca and Takeda have agreed a multi-million pound deal for AZ to acquire the Japanese firm’s core respiratory business, including …

News
clinical_trial-web

Pharma deals crucial to cutting R&D costs

December 16, 2015
Research and Development GlobalData, R&D, drug development, pharma, research and development

With the average cost of getting a novel drug to market at almost $2.5 billion, and few products achieving blockbuster …

News
Monopoly board tax

Pharma companies warned on patent box changes

December 16, 2015
Research and Development R&D, patent box, pharma, research and development, tax

Proposed Government changes to legislation will require businesses to track and trace all R&D expenditure if they want to continue …

News
R&D researcher

More breakthroughs in cancer pose the question: Who pays for them?

December 16, 2015
Research and Development Cancer, drug access, immunotherapy, oncology

The molecular revolution over the last decade has done much to help turn cancer into an illness that can be …

Feature
NHS sign

NICE rejects BMS cancer drug in draft guidance

December 16, 2015
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, NHS, NICE, lung cancer, nivolumab, non small cell lung cancer, non-small cell lung cancer, opdivo

In draft guidance, NICE has chosen not to recommend Bristol-Myers Squibb’s Opdivo for the treatment of locally advanced or metastatic …

News
Kadcyla

NICE says no to NHS funding for Kadcyla

December 16, 2015
Research and Development, Sales and Marketing Breast Cancer Now, Kadcyla, NHS, NICE, Roche, advanced breast cancer, breast cancer

NICE has turned down Roche’s application for NHS funding for Kadcyla as a treatment for a type of advanced breast …

News
The Gateway to Local Adoption Series

Latest content

Campaign highlights low expectations among patients with depression

May 7, 2026

Practical AI toolkit launched to help manufacturers cut through complexity

May 6, 2026

Syngene appoints Maninder Kapoor Puri as CHRO

May 6, 2026

BioPhorum acquires PharmaX Solutions

May 5, 2026

Syngene appoints Abhijit Zutshi as CCO

May 5, 2026